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Background: Short dimeric or mulitmeric peptides derived from a highly conserved stretch of amino acids from
gammaretroviral envelope proteins has been found to have immunosuppressive properties in vitro. Here we test
the hypothesis that such immunosuppressive peptides may serve as immunomodulatory reagents for treatment
of inflammatory disorders.
Results: The anti-inflammatory effect of a synthetic retrovirus-derived immunosuppressive peptide of 17 amino
acids was tested in two murine skin inflammation models, a TPA-induced acute toxic contact eczema model
and an oxazolone-induced allergic contact dermatitis. Overall, mice (n = 24) treated with a topically applied
cream containing the dimeric immunosuppressive peptide exhibited a reduction of 28.8% in ear thickness
(range 20.1-42.5), whereas the application of a scrambled peptide dimer or a monomer of the immunosuppressive
peptide remained without effect (p = 0.028). Furthermore, ear biopsies from mice treated with the dimeric
immunosuppressive peptide showed a significant reduction in mRNA of the pro-inflammatory cytokines TNF-α,
IL-17C, and IL-6 as well as the chemokine CXCL2 compared to mice treated with control peptides.
Conclusion: Using two murine skin inflammation models, we show that an immunosuppressive retroviral peptide
is capable of reducing inflammatory disorders. The results indicate that virus-derived immunosuppressive peptides
capable of down-regulating several proinflammatory cytokines may represent a novel class of drugs for the
treatment of excess inflammation.Background
Several inflammatory diseases are characterized by an
unbalanced inflammation and an increased expression of
inflammatory cytokines such as TNF-α, IL-6, IL-17A,
IL-17C, IL-20, IL-22, IL-23, IFNγ and CXCL2. Especially
TNF-α, IL-17A and IL-12/IL-23 are believed to play a
key role in the pathogenesis of psoriasis, which is con-
firmed by the successful use of antibodies directed against
these cytokines in the treatment of psoriasis [1-3]. A sub-
set of these cytokines such as TNF-α, IL-17C, IL-6 and
CXCL2) have also been implicated in sepsis [4-8].
It has been known for many years that retroviruses are
capable of inhibiting proliferation of immune cells upon
stimulation [9-11]. These effects have been localized to* Correspondence: martol@rm.dk
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reproduction in any medium, provided the orthe viral fusion protein. Expression of such fusion
proteins is sufficient to enable allogenic cells to grow
into a tumor in immune competent mice [12]. Immuno-
suppressive (ISU) fusion proteins have been found in a
variety of different viruses with type I fusion mechanism
such as retroviruses like MPMV and HIV and in
filoviruses such as Ebola and Marburg [13-17]. This ISU-
activity was in all these cases located to a very well-
defined structure in the transmembrane protein (Figure 1)
the ISU effects range from significant inhibition of lym-
phocyte proliferation [14,15] cytokine skewing (up regu-
lating IL-10; down regulating TNF-α, IL-12, IFN-γ) [18],
inhibition of monocytic burst [19], polyclonal B cell acti-
vation and cytotoxic T cell activity [20]. Peptides spanning
the ISU domain are as active as the whole protein in these
assays but only when presented in a dimeric form or
coupled to a carrier protein (i.e. >monomeric). Such mul-
timeric peptides are capable of reducing or abolishingl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic representation of the retroviral envelope protein (not to scale). Top figure displays some of the functional elements in
the transmembrane subunit. The fusion peptide (FP) and the Heptad Repeat I/II (HR) followed by the membrane transversing region (TM). The
Immunosuppressive Domain (ISD) is located just N-terminal of the highly conserved CC-motif forming a vital disulphide bond. Stipulated lines
indicate amino acid position in the alignment. Fr-MLV Friend Murine Leukemia Virus; FeLV Feline Leukemia Virus; GALV Gibbon Ape Leukemia
Virus; MPMV Mason-Pfizer Monkey Virus; ALV Avian Leukosis Virus; HTLV Human T-lymphotropic Virus. GeneBank accession numbers indicated
in parenthesis.
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of activated T-cells.
The ISU-domain has been investigated extensively
using a 17-meric peptide (CKS-17) derived from murine
leukemia virus (MLV) which shows significant im-
munosuppressive activity in vitro as described above
[4,5,21-23].
The ability of CKS-17 to repress T-cell mediated immune
responses makes this peptide an interesting drug candidate
for the treatment of inflammatory diseases. The aim of
this study was to verify the in vivo effects of a retrovirally
derived CKS-17 peptide on the immune system. We used
two known mouse models for skin inflammation: Acute
allergic contact dermatitis model and TPA toxic eczema
model [24,25].
In both models, the application of the peptide reduced the
inflammation induced by the irritants, thereby confirming
the viability of utilization of this virus-derived peptide for
treatment of inflammatory diseases.Results
In order to retain the ISU-peptide on the ears of the
mice for longer periods the dissolved peptide was mixed
with Natusan®, First Touch Protection cream at a 1:1
ratio to create a homogenous solution. All peptides were
freshly dissolved at the start of treatments and stored for
4°C during the animal experiments.Acute toxic contact eczema model
Two variants of the TPA-induced acute toxic contact ec-
zema model were used to evaluate the anti-inflammatory
potential of topical applied CKS-17 peptide. Initially,
mice were pretreated for 3 days with peptide-containing
cream followed by induction of ear inflammation by
TPA. Figure 2A depicts the time-course. Evidently, mice
treated with CKS-17 peptide have significantly reduced
swelling of the ears upon inflammation induction. The
direct comparison with a scrambled peptide in Figure 2B
(day 1) points to a specific effect of CKS-17 dimer,
which is significantly more potent than the scrambled
peptide control to reduce ear inflammation (p < 0.001).
In the same model an experiment was performed in
which inflammation was induced five days prior to treat-
ment with peptide cream (Figure 3A). In this setup a
monomer peptide vs a dimer was tested since the ISU-
activity of the peptides are consistently correlated with
di- or multimeric forms of the peptides [14,19,26]. This
was confirmed in a direct comparison experiment, where
CKS-17 dimer-containing cream significantly reduced
ear inflammation in contrast to the monomeric peptide.
Figure 3B clearly shows a significant reduction of in-
flammation two days after CKS-17 dimer treatment in
contrast to the monomeric peptide (p = 0.003, Student’s
t-test). Monomeric peptide was not different from the
pure cream vehicle. Furthermore, in the same expe-
riment we performed a direct comparison to a potent
Figure 2 Earthickness in an acute toxic contact eczema model (C57BL/6 mice). A) Acute toxic contact eczema model in C57BL/6 mice
(n = 6 pr group) pretreated with peptide cream prior to application of TPA. CKS-17 dimér and scrambled CKS-17 dimér used at a concentration
of 100 uM. Ear thickness measured each day from onset of TPA treatment. The graph depicts mean with SEM. B) Box-plot with whiskers
(5–95 percentile) of ear thickness measurement at day 1 after TPA application. Treatment group comparison performed by students t-test.
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(Clobetasol propionate 0.05%). Clobetasol propionate
treatment was very potent in this model and reduced
inflammation close to the basal level with minimal inter-
animal variation.
Oxazolone-induced murine allergic contact dermatitis
This model is representative of allergic contact derma-
titis induced inflammation by sensitizing the mice 7 days
prior to challenge. Three days before induction of
inflammation the mice were treated with peptide-
containing cream. Evidently, as in the TPA-induced
eczema model treatment with CKS-17 containing cream
lowered swelling of the ears (Figure 4A) following
inflammation induction by oxazolone (day 0). However,
the effect was less pronounced at day two post oxazolonechallenge (p = 0.068 CKS-17 vs. scrambled, Student’s t-test)
as shown in the box-plot in Figure 4B. In general, this
contact dermatitis mouse model induces much less
inflammation of the ears in comparison to the TPA mouse
model. The results of a total of four independent experi-
ments (3 eczema studies and 1 contact dermatitis) each
with 6 mice pr treatment group are compiled in Figure 5.
The figure depicts the relative reduction in ear thickness
of the treatment groups (scrambled/monomer, CKS-17 or
Clobetasol propionate) compared with TPA or Oxazolone
alone. Across the experiments the reduction in the CKS-
17 treatment group ranged from 20-43% with no effect of
scrambled/monomer. Clobetasol propionate reduced the
swelling of the ears by 80% in the single study where it
was applied. The consistent reduction of treatment with
CKS-17-containing cream independent of the model and
Figure 3 Earthickness in an acute toxic contact eczema model (BALB/CJ mice). A) Acute toxic contact eczema model in BALB/cJ mice
(n = 6 pr group) with application of TPA at day 0 and treatment with peptide cream at day 5. CKS-17 dimér and CKS-17 monomér used at a
concentration of 100 uM. The graph depicts mean with SEM. B) Box-plot with whiskers (5–95 percentile) of ear thickness measurement at day
7 after TPA application. Treatment group comparison performed by Student’s t-test. Clobetasol propionate 0.05% (GSK, UK) applied neat without
dilution with PBS.
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treatment with a scrambled peptide (p = 0.028, Mann
Whitney test).
The impact of CKS-17 treatment on cytokines implicated
in inflammatory diseases
RNA from ear biopsies of the mice treated with TPA
(mice depicted in Figure 2) was harvested and subjected
to mRNA relative quantification of IL-1α, IL-6, IL-10,
IL-17C, TNF-α and CXCL2. All expression levels were
adjusted for input mRNA by GAPDH gene expression
and the results normalized to levels for vehicle only
treated mice. There was a clear and significant reduction
of mRNA levels of IL-17C, TNF-α, IL-6 and CXCL2 in
mice treated with CKS-17 containing cream (Figure 6,
left column). When correlating the relative mRNA
expression of these cytokines/chemokines to the ear
thickness of individual animals, a statistically significant
correlation was observed (Figure 6, right column). Inturn, expression levels of neither IL-1α nor IL-10 were
affected by treatment with CKS-17-containing cream
compared to cream with scrambled peptide. Notably,
plotting the expression levels of IL-1α and IL-10 against
the ear thickness revealed no linear correlations where
observed (Figure 6, right column). The results are sum-
marized in Table 1.
Interestingly, treating mouse ears with cream containing
CKS-17 peptide results in a potent blockage of TNF-α
mRNA expression (mean index (range) 0.3(0.17-0.52)) to
levels below the background in untreated animals in the
vehicle control group (mean index (range) 1(0.49-1.51)).
Discussion
In this report we have tested the hypothesis that a
retrovirus-derived immunosuppressive peptide may re-
duce inflammation. We found that a topically delivered
retroviral derived peptide (CKS-17) reduced ear inflam-
mation in two different mouse models. Neither a dimeric
Figure 4 Earthickness in an oxazolone-induced murine allergic contact dermatitis model. A) Oxazolone-induced murine allergic contact
dermatitis model in C57BL/6 mice (n = 6 pr group). At day −7 mice were sensitized by oxazolone on the abdomen. On day −3 ears were
pretreated with cream followed by challenge by oxazolone on the ears at day 0. The graph depicts ear thickness mean with SEM. B) Box-plot
with whiskers (5–95 percentile) of ear thickness measurement at day 2 after Oxazolone application. Treatment group comparison performed by
Student’s t-test.
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ISU-peptide had any effect, similar to what was previously
reported in cell-culture-based assays [9,10,14,15,18-20,26].
The lowering of inflammation in the mouse models can
be coupled to significantly reduced expression of key
inflammatory cytokines like IL-6, TNF-α and IL-17C.
These results complement those of Cianciolo et al.
who recently reported that the CKS-17 ISU-peptide or
shorter versions thereof had an immunosuppressive
effect in mouse models of inflammatory peritonitis and
disseminated intravascular coagulation [27]. Parallel
work on hydrophobic regions of HIV-1 gp41, both the
fusion peptide and the ISU domain, has suggested con-
trol of T cell activation [17,28]. A different applicability
of modifying the ISU-peptide from HIV-1 was reported
by Morozov and colleagues who were able to enhancethe vaccine induced IgG titer towards recombinant
gp41 [29].
Previously, TPA-induced skin inflammation in mice
has been shown to involve potent upregulation of TNF-
α [30,31]. Here we report that TNF-α expression levels
were the most severely affected cytokine level by peptide
treatment. Despite a four-fold increase in mRNA by
TPA treatment the application of CKS-17 containing
cream reduced TNF-α expression to below baseline
levels (average of 70% reduction compared to baseline).
In addition, levels of another important regulator in
autoimmune diseases, IL-17C was significantly reduced
upon treatment of inflamed ears with cream containing
retroviral peptide. Recently, anti-IL-17A receptor anti-
bodies have proven successful in early clinical trials
[2,30].
Figure 5 Relative comparison of ear thickness across 4
independent studies. Included in analysis: three studies in the
acute toxic contact eczema model and one study in the oxazolone-
induced murine allergic contact dermatitis model. Each point
represents one experiment with the average relative ear thickness
from each 6 mice. The relative induction calculated as [(ear thickness
treatment two days post challenge - baseline ear thickness)/
(ear thickness TPA/Oxazolone two days post challenge - baseline
ear thickness)]*100%.
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is not regulated by CKS-17 peptide application. Consid-
ering the effect of IL-1α in the contact acute eczema
model this was somewhat surprising although in agree-
ment with earlier studies of the intrinsic effects of
retrovirus-derived envelope peptides highlighting that
CKS-17 does not block production of IL-1α but reduce
the immunobiological effect [20]. The varied effect on
several key cytokines suggests that the local application
of peptide containing cream pursued in this study could
be of greater relevance than systemic use of monoclonal
antibodies mainly because of the plethora of targets and
the fact that for example anti-TNF-α blockers carry
increased infection risks [32].
In the model of Oxazolone induced inflammation a
similar trend was observed in that ear inflammation was
reduced in peptide treated mice. The degree of inflam-
mation induced in this model is of a smaller magnitude.
In turn, the relative reduction by peptide treatment was
comparable to what was obtained in the TPA-induced
model suggesting that the peptide did indeed impact this
model as well, although the inhibitory effect failed to
reach statistical significance. In this model we have
previously shown mitogen-activated protein kinase AP
(MAPKAP) kinase 2 regulated TNF-α as important for
ear inflammation [24].Conclusion
We have shown that the immunosuppressive retroviral
peptide CKS-17 is capable of reducing proinflammatory
cytokines as well as the level of inflammation as
measured by ear thickness in two mouse models of
inflammatory skin disease. Together with the work of
Cianciolo et al. [27] our results indicate that virus-
derived immunosuppressive peptides capable of down-
regulating several proinflammatory cytokines such as
TNF-α, IL-6, and IL-17C may represent a novel class of
drugs for the treatment of excess inflammation.
Methods
Peptides
CKS-17 peptide (LQNRRGLDLLFLKEGGLC) or scram-
bled CKS-17 (LGGEKLFLLDLGRRNQLC) both linked
into dimers via the C-terminal cysteine were purchased as
lyophilized powder from Anaspec (California, USA). CKS-
17 monomer was purchased without the C-terminal disul-
phide linkage. All peptides were dissolved in sterile water.
Mice
BALB/cJ and C57BL/6 mice were purchased from Taco-
nic Europe (Ry, Denmark). All mice used in this study
were female and 6–8 weeks of age when experiments
were initiated. The animals were kept in animal facilities
that maintained a temperature of 19–25°C, and a 12-
hour day/night cycle. They were given access to food
and water ad libitum. All experiments were approved by
the Committee for Animal Experiments in Denmark.
Acute toxic contact eczema model
Two different dosings were pursued in this model.
Firstly, C57BL/6 mice were treated once daily from
day −3 until day 3 on the ears with cream (commercially
available baby lotion; Natusan®, First Touch Protection
cream) + 50% H2O) alone, cream + scrambled peptide or
cream + CKS-17 peptide. Before the first application of
cream at day −3 the ear thickness was measured. At day
0 and day 2 (3 hours before treatment with cream) the
mice were treated with phorbol 12-myristate 13-acetate
(TPA)(Sigma-Aldrich, St Louis, MO, cat no. P8139) on
the ears (2 μg/ear). TPA was dissolved in acetone. Before
the first challenge of TPA the ear thickness was
measured (day 0) and again post-challenge at the times
indicated, using a Mitutyo digimatic indicator. In the
second experiment, BALB/cJ were treated at day 0, 2, 5
and 7 with phorbol 12-myristate 13-acetate (TPA)
(Sigma-Aldrich, St Louis, MO, cat no. P8139) on the
ears (2 μg/ear). TPA was dissolved in acetone. Before the
first challenge of TPA the ear thickness was measured
(day 0) and again post-challenge at the times indicated,
using a Mitutyo digimatic indicator. At day 5 and 7 the
mice were treated one time with either cream alone,
Figure 6 (See legend on next page.)
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Figure 6 Relative mRNA expression levels from ear biopsies of TPA treated mice. Left columns depict Box-plot with whiskers (5–95 percentile)
of the relative mRNA expression levels (Vehicle only mice index 1). On graphs statistical differences (Mann Whitney test) marked by p-value or
as n.s. (non significant) between scrambled and CKS-17 treated mice. Right column depicts xy-plots of the Log10 normalized relative mRNA
expression and ear thickness. Linear relationships were determined by Spearman correlation.
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betasolpropionat 0.05% cream formulation applied neat
(GSK, UK). The mice were anaesthetised during the ear
measurement.
Oxazolone-induced murine allergic contact dermatitis
4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone)
was purchased from Sigma-Aldrich (cat no. E0753). Oxa-
zolone was dissolved in acetone. At day −7 mice were sen-
sitized with 1.5% oxazolone by application to the clipped
abdomen (100 μl). Once daily from day −3 until day 1 the
ears of the mice were treated with cream (commercial avail-
able baby lotion; Natusan®, First Touch Protection cream +
50% H2O) alone, cream+ scrambled peptide or cream +
CKS-17 peptide. Before the first application of cream
at day −3 the ear thickness was measured. At day 0
the mice were challenged with 0.5% oxazolone at the ears
(20 μl per ear). This was done 3 hours prior to treatment
with the different cream formulations. Before challenge (day
0), the ear thickness was measured and again post-challenge
at the times indicated, using a Mitutyo digimatic indicator.
RNA isolation
At termination of one study of acute toxic contact eczema
punch biopsies (4 mm) from mice ears were transferred to
1 ml of −80°C cold RNAlater-ICE (Ambion inc., Austin,
TX). Samples were kept at −80°C until 24 hours before
RNA purification at which time they were transferred
to −20°C. On RNA purification, biopsies were remo-
ved from RNAlater-ICE and transferred to 175 μl of SV
RNA lysis buffer added β-mercaptoethanol (SV Total
RNA Isolation System; Promega, Madison, WI) and ho-
mogenized. RNA purification was completed according to
the manufacturer’s instructions (SV Total RNA Isolation
System; Promega). RNA was stored until further use







CXCL2 1(0.41–1.59) 1162(402–2846)Quantitative polymerase chain reaction (qPCR)
For reverse transcription, Taqman Reverse Transcription
reagents (Applied Biosystems, Foster City, CA, U.S.A.)
were used. For qPCR we used Platinum® qPCR SuperMix-
UDG (Invitrogen, Carlsbad, CA, U.S.A.) with primers and
probes were Taqman 20× Assays-On-Demand (FAM-la-
beled MGB-probes) gene expression assay mix (Applied
Biosystems). Each sample was loaded as triplets and
analyzed on a Rotorgene-3000 real-time PCR machine
(Corbett Research, Cambridge, U.K.). Relative gene ex-
pression levels were determined by using the relative
standard curve method as outlined in User Bulletin 2 (ABI
PRISM 7700 sequencing detection system, Applied Bio-
systems). Briefly, a standard curve for each gene was made
of fourfold serial dilutions of total RNA from a punch
biopsy from the ears of mice. The curve was then used to
calculate relative amounts of target mRNA in the samples.
As housekeeping GAPDH was used. Assay ID for the
primers and probes used in this study were as follows:
IL-17c (Mm00439619_m1); TNF-α (Mm00443258_m1);
IL-1α (Mm00439620_m1); IL-6 (Mm00446190_m1); IL-10
(Mm00439616_m1); CXCL2 (Mm00436450_m1); GAPDH
(Mm99999915_g1).Statistics
Comparisons of ear thickness and relative mRNA levels
between treatment groups were performed using a stu-
dent’s t-test. Correlations between ear thickness and
mRNA levels were determined using spearman correla-
tions. Lastly, the percentage effect on reduction in ear
thickness between scrambled and CKS-17 treated groups
across four independent mouse experiments were com-
pared using a Mann–Whitney test. All p-values re-
ported are two-tailed and we set the significance level
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